What is the typical dosage and treatment approach for an adult patient with a history of gastrointestinal issues, such as gastroesophageal reflux disease (GERD) and peptic ulcers, who is prescribed Ranitidine (Zantac)?

Ranitidine for GERD and Peptic Ulcers: Important Update

Critical Notice: Ranitidine Withdrawal

Ranitidine (Zantac) has been withdrawn from the market due to contamination concerns and should no longer be prescribed. 1 Patients previously on ranitidine require transition to alternative therapies.

---

Recommended Replacement Strategy

First-Line Replacement: Proton Pump Inhibitors (PPIs)

For adult patients with GERD and peptic ulcers previously treated with ranitidine, PPIs are now the preferred first-line therapy rather than switching to another H2-receptor antagonist. 2, 1

• PPIs demonstrate superior efficacy compared to ranitidine for both symptom control and healing of erosive esophagitis 2, 3
• Standard-dose PPI once daily should be initiated, taken 30-60 minutes before the first meal of the day 2
• If inadequate response after 2-4 weeks, escalate to twice-daily PPI dosing (before breakfast and dinner) 2, 4

Alternative H2-Receptor Antagonist: Famotidine

If an H2-receptor antagonist is preferred, famotidine is the recommended replacement for ranitidine. 1

• Famotidine is 20-50 times more potent than cimetidine and does not have contamination issues 1
• Famotidine does not interfere with cytochrome P-450 metabolism, making it safer for patients on multiple medications 1
• Dosing: Famotidine 20-40 mg twice daily for GERD/peptic ulcers 2

---

Historical Ranitidine Dosing (For Reference Only - No Longer Available)

Adult Dosing (FDA-Approved) 5

GERD:

• 150 mg twice daily 5

Erosive Esophagitis:

• 150 mg four times daily for acute treatment 5
• 150 mg twice daily for maintenance of healing 5

Duodenal/Gastric Ulcers:

• 150 mg twice daily, or 300 mg once daily at bedtime 5
• Maintenance: 150 mg at bedtime 5

Pathological Hypersecretory Conditions (Zollinger-Ellison):

• 150 mg twice daily, with doses up to 6 g/day in severe disease 5

Pediatric Dosing (Ages 1 Month to 16 Years) 5

• GERD/Erosive Esophagitis: 5-10 mg/kg/day divided in 2 doses, maximum 300 mg/day 2, 5
• Peptic Ulcers: 2-4 mg/kg twice daily, maximum 300 mg/day 5

---

Critical Limitations of H2-Receptor Antagonists

Tachyphylaxis Development

All H2-receptor antagonists, including ranitidine and famotidine, develop tachyphylaxis within 6 weeks of continuous use, significantly limiting their long-term effectiveness. 2, 1

• This rapid tolerance development makes H2RAs suboptimal for chronic GERD management 2
• Switching to PPIs should be considered if symptoms persist beyond 4-6 weeks 1

Inferior Efficacy Compared to PPIs

H2-receptor antagonists are less effective than PPIs for healing erosive esophagitis and controlling GERD symptoms. 2

• In patients with persistent GERD symptoms on ranitidine, omeprazole provides faster and more complete symptom resolution 3, 6
• At 8 weeks, 80% of patients with grade 2+ esophagitis healed with omeprazole versus only 40% with ranitidine 3
• Complete heartburn resolution occurred in 46% of omeprazole patients versus 16% with ranitidine 6

Limited Role in NSAID-Related Ulcers

Standard doses of H2-receptor antagonists do not prevent most NSAID-related gastric ulcers. 2

• PPIs are superior to ranitidine for preventing NSAID ulcer recurrence and controlling symptoms 2

---

Current Treatment Algorithm for GERD/Peptic Ulcers

Step 1: Lifestyle Optimization 2

• Weight management, dietary modifications, elevation of head of bed
• Avoid late-night meals, trigger foods, tobacco, and alcohol 2

Step 2: Initial Pharmacotherapy 2, 1

• Start with standard-dose PPI once daily (e.g., omeprazole 20 mg, lansoprazole 30 mg) 2
• Take 30-60 minutes before first meal 2

Step 3: Escalation if Inadequate Response 2, 4

• Increase to twice-daily PPI dosing after 2-4 weeks if symptoms persist 2, 4

Step 4: Adjunctive Therapy for Breakthrough Symptoms 2, 4

• Nocturnal symptoms: Add bedtime H2RA (famotidine 20-40 mg) 2, 4
• Post-prandial/nighttime symptoms: Consider alginate antacids 2, 4
• Regurgitation/belching: Consider baclofen 2

Step 5: Long-Term Management 2

• Wean to lowest effective PPI dose for most patients once symptoms controlled 2
• Exceptions requiring indefinite PPI therapy: 2
  • Los Angeles grade B or greater erosive esophagitis 2
  • Barrett's esophagus 2
  • Peptic stricture 2
  • Severe GERD (grade C/D esophagitis, AET >12%) 2

---

Special Populations

Patients on Dual Antiplatelet Therapy

• Famotidine is preferred over PPIs to avoid potential drug interactions with clopidogrel 1

Renal Impairment (Historical Ranitidine Dosing)

• For creatinine clearance <50 mL/min: 150 mg every 24 hours 5
• Adjust timing to coincide with end of hemodialysis 5

Pediatric Patients

• Famotidine 1 mg/kg/day divided in 2 doses is the preferred H2RA for children ages 1 month to 16 years 2, 1
• PPIs (omeprazole, lansoprazole, esomeprazole) are FDA-approved for children ≥1-2 years depending on formulation 2

---

Common Pitfalls to Avoid

1. Do not continue H2RA monotherapy beyond 6 weeks due to tachyphylaxis 1
2. Do not use H2RAs as first-line therapy for moderate-to-severe GERD or erosive esophagitis—PPIs are superior 2, 1
3. Avoid cimetidine due to antiandrogenic effects, gynecomastia risk, and cytochrome P-450 interactions 2, 1
4. Ensure proper PPI timing (30-60 minutes before meals) to maximize efficacy 2, 4
5. Do not prescribe ranitidine—it has been withdrawn from the market 1